| Chai Yu-xiao,Han Yu,Wang Bing,Zhang Yi,Qu Xing-long. Clinical study of docetaxel plus S-1 as neoadjuvant therapy for advanced gastric cancer. Oncol Transl Med, 2016, 2: 80-83. |
| Clinical study of docetaxel plus S-1 as neoadjuvant therapy for advanced gastric cancer |
| Received:June 06, 2015 Revised:April 11, 2016 |
| View Full Text View/Add Comment Download reader |
| KeyWord:advanced gastric cancer; neoadjuvant chemotherapy; surgery; curative operation |
| Author Name | Affiliation | E-mail | | Chai Yu-xiao | Department of oncosurgery,Minhang branch,Cancer hospital,Fudan university | chaiyuxiao@163.com | | Han Yu | Department of oncosurgery,Minhang branch,Cancer hospital,Fudan university | arowana2010@163.com | | Wang Bing | Department of oncosurgery,Minhang branch,Cancer hospital,Fudan university | 1179514384@qq.com | | Zhang Yi | Department of oncosurgery,Minhang branch,Cancer hospital,Fudan university | ansonzhang0226@hotmail.com | | Qu Xing-long | Department of oncosurgery,Minhang branch,Cancer hospital,Fudan university | quxl681@163.com |
|
| Hits: 6033 |
| Download times: 7781 |
| Abstract: |
| Objective To evaluate the efficacy, toxicity, and operative complications of docetaxel in combination with
S-1 for treating patients with advanced gastric cancer.
Methods From July 2013 to December 2014, 30 patients with advanced gastric cancer were treated with
i.v. docetaxel 75 mg/m2 on day 1 and oral S-1 60 mg/m2 bid on days 1–14 every 3 weeks. The efficacy and
toxicity were evaluated after two chemotherapy cycles.
Results The overall treatment response (complete response [CR] partial response [PR]) was 76.6%
(23/30), CR was 6.7% (2/30), PR was 70.0% (21/30), SD was 23.3% (7/30), and progression disease was
0% (0/30). All patients were treated surgically. Twenty-six patients received radical surgery; of them, 23
received D2 lymph node dissection. The other four patients received exploratory celiotomy. No patients died
in the group, and the adverse reactions included neutropenia, diarrhea, nausea, and vomiting.
Conclusion Docetaxel/S-1 combination is highly active, safe, and well tolerated in patients with advanced
gastric cancer. Further investigations in randomized studies are warranted. |
| Close |
|
|
|